Home > News > Biocon and Abraxis announce approval of Abraxane in India
November 29th, 2007
Biocon and Abraxis announce approval of Abraxane in India
Abstract:
Biocon and Abraxis BioScience, an integrated global biopharmaceutical company, have announced the approval by the country's Drug Controller General to market Abraxane for injectable suspension (paclitaxel protein-bound particles) in India for the treatment of breast cancer. Commercial introduction of Abraxane in the Indian market is expected in 2008, following the completion of the appropriate importation certifications. "The approval of Abraxane in India is an important step in providing access to the NAB (nanoparticle albumin bound) technology globally," said Patrick Soon-Shiong, Managing Director, Chairman and Chief Executive Officer of Abraxis. "In partnership with Biocon, we are excited to offer physicians in India this important advance in the treatment of breast cancer."
Source:
expresspharmaonline.com
Bookmark:
| Related News Press |
Govt.-Legislation/Regulation/Funding/Policy
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||